Table 1.
Patient characteristics.
| Total patients (n = 110) | NonAA (n = 56) | AA (n = 54) | p-valued |
|---|---|---|---|
| Ethnicity | |||
| Hispanic or Latino | 0 (0.0%) | 1 (1.9%) | 0.3657 |
| Not Hispanic or Latino | 41 (73.2%) | 43 (79.6%) | |
| Unknown | 15 (26.8%) | 10 (18.5%) | |
| Clinical variables | |||
| Age (years), median | 56.0 | 59.5 | 0.795a |
| Interquartile range (years) | 49.0–67.3 | 50.8–66.0 | |
| Follow-up time (years), median | 5.9 | 6.4 | 0.344a |
| Interquartile range (years) | 2.0–10.9 | 3.0–10.9 | |
| Recurrence rate, n (%) | 0.0238b | ||
| Yesb | 8 (14.3%) | 18 (33.3%) | |
| Nob | 46 (82.1%) | 34 (63.0%) | |
| Unknown | 2 (3.6%) | 2 (3.7%) | |
| Adjuvant chemotherapy, n (%) | 0.0569c | ||
| Anthracycline + Taxanec | 24 (42.9%) | 18 (33.3%) | |
| Otherc | 10 (17.9%) | 21 (38.9%) | |
| None | 9 (16.1%) | 15 (27.8%) | |
| Unknown | 12 (21.4%) | 0 (0%) | |
| Chronic conditions | |||
| Obesity (BMI > 30), n (%) | 14 (25.0%) | 24 (44.4%) | 0.045 |
| Hypertension, n (%) | 22 (39.3%) | 36 (66.7%) | 0.0046 |
| Type 2 diabetes mellitus, n (%) | 5 (8.9%) | 21 (38.9%) | 0.0003 |
| Autoimmunity (SLE, Sjogren’s Disease, RA, IBD, MS, Type I Diabetes Mellitus, Graves’ or Hashimoto’s Disease), n (%) | 6 (10.7%) | 7 (13.0%) | 0.774 |
| Chronic kidney disease, n (%) | 3 (5.4%) | 8 (14.8%) | 0.121 |
| Hyperlipidemia, n (%) | 17 (30.4%) | 17 (31.5%) | 1.000 |
| Pathological variables | |||
| Stage, n (%) | 0.407 | ||
| I | 22 (39.3%) | 20 (37.0%) | |
| II | 28 (50.0%) | 32 (59.3%) | |
| III | 6 (10.7%) | 2 (3.7%) | |
| Tumor size | 0.269 | ||
| T1 | 29 | 26 | |
| T2 | 24 | 24 | |
| T3 | 1 | 4 | |
| T4 | 2 | 0 | |
| Nodal status | 0.488 | ||
| N0 | 33 | 32 | |
| N1 | 14 | 18 | |
| N2 | 4 | 2 | |
| NA | 5 | 2 | |
| Histological grade, n (%) | 1.000 | ||
| Well-differentiated | 1 (1.8%) | 0 (0.0%) | |
| Moderately differentiated | 10 (17.9%) | 9 (16.7%) | |
| Poorly differentiated | 45 (80.4%) | 45 (83.3%) | |
| Breast cancer biomarkers | |||
| ESR1 mRNA normalized expression, median (CI) | 7.531 (7.000–7.924) | 7.548 (7.287–8.435) | 0.6339 |
| ERBB2 mRNA normalized expression, median (CI) | 11.13 (10.76–11.25) | 11.05 (10.90–11.57) | 0.8278 |
| PGR mRNA normalized expression, median (CI) | 5.661 (5.355–6.133) | 6.087 (5.597–6.678) | 0.6499 |
| MKI67 mRNA normalized expression, median (CI) | 13.57 (12.50–13.62) | 13.57 (12.68–13.63) | 0.9981 |
ap-values determined by Mann–Whitney Test.
bYes versus No only.
cAnthracycline + taxanes vs. Other only.
dp-values determined by Fisher’s Exact Test unless otherwise specified.